Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow MANE by emailGet an email when MANE pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MANE, unsubscribe in one click. Privacy
📣 What MANE Says Is Next
second half of 2026 · “Twelve-month data from Study ‘302’ are anticipated in the second half of 2026.”
Company press release, Aug 11, 2026 · SEC filing
2H26 · “Progress in Study ‘302’; 12-Month Data Anticipated in 2H26: In April 2026, Veradermics reported positive topline data from Part A of Study ‘302’, a four-arm, multicenter, randomized, double-blinded, placebo-controlled Phase 2/3 clinical trial Exhibit 99.1 evaluating VDPHL01 8.5 mg in males with mild-to-moderate pattern hair loss.”
Company press release, Aug 11, 2026 · SEC filing
2H26 · “Phase 3 Study ‘304’; Topline Data Anticipated in 2H26: T opline data from Study ‘304’, a confirmatory Phase 3 trial evaluating the safety and efficacy of VDPHL01 in the treatment of male pattern hair loss, are expected in the second half of 2026.”
Company press release, Aug 11, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full MANE picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MANE and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.